This is spot on. Anavex has run a number of late stage trials now in 3 significant indications without adequate therapy: Rett, PD, AD. All trials have been run rigorously and conformed with regulatory agencies' guidance. All done with rigorous focus. All done so as to mutually reinforce each other. All done while simultaneously building a real pipeline.
Only over the past 18 months has Anavex begun to build out its infrastructure: a clear sign that commercial launch is very close: 10 employees to 37 year-over-year.
In 5 years, people will ask themselves how did they miss this opportunity? And ask themselves how to identify the next Anavex.
News 
Market Data 
Discover 
